Anavex Life Sciences Corp. (AVXL)
1.15
+0.04
(+3.60%)
USD |
NASDAQ |
Nov 06, 16:00
1.145
0.00 (0.00%)
After-Hours: 20:00
Anavex Life Sciences Research and Development Expense (Annual) : 37.59M for Sept. 30, 2025
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| September 30, 2025 | 37.59M |
| September 30, 2024 | 41.84M |
| September 30, 2023 | 43.72M |
| September 30, 2022 | 37.92M |
| September 30, 2021 | 32.98M |
| September 30, 2020 | 25.23M |
| September 30, 2019 | 22.26M |
| September 30, 2018 | 13.34M |
| September 30, 2017 | 10.67M |
| September 30, 2016 | 7.254M |
| Date | Value |
|---|---|
| September 30, 2015 | 2.272M |
| September 30, 2014 | 0.7324M |
| September 30, 2013 | 0.2638M |
| September 30, 2012 | 2.654M |
| September 30, 2011 | 2.597M |
| September 30, 2010 | 2.729M |
| September 30, 2009 | 2.140M |
| September 30, 2008 | 1.480M |
| September 30, 2007 | 0.9597M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Vaxcyte, Inc. | 794.31M |
| Foghorn Therapeutics, Inc. | 82.13M |
| Connect Biopharma Holdings Ltd. | 37.80M |
| Caribou Biosciences, Inc. | 109.44M |
| Arrowhead Pharmaceuticals, Inc. | 585.26M |